110 Startups
  • Sector
  • Participated in
  • Year of participation

Exbiome

  • 2015
  • Diagnostics
  • Venture Challenge
Simple blood tests to detect cancer

ExCulture

  • 2023
  • Therapeutics
  • Venture Challenge
Opposed to the current heparin production method, our technology has the potential to ensure supply security, reduce risk of contamination and remove dependency on animal material.

Exolumen (Anatomy Projector)

  • 2022
  • Medical Device
  • Venture Challenge
We created a method of projecting a surgical planning onto the patient. This way the surgeon spends less time on preparation (20 min) and performs surgeries faster (19 min). The prototype is in continuous use in Radboudumc (400+ surgeries).

Exovectory

  • 2018
  • Enabling Technology
  • Therapeutics
  • Venture Challenge
Optimal delivery to ensure effective treatment of cancer and more

Fenix Therapeutics

  • 2023
  • Therapeutics
  • Venture Challenge
Fenix Therapeutics addresses the critical challenges in cancer treatment by focusing on the Notch pathway, a key factor in therapy resistance in many human cancers.

Flexupp (previously Saturn)

  • 2023
  • Medical Device
  • Venture Challenge
Saturn offers a personalized solution for Pelvic Organ Prolapse by providing a pessary with a perfect fit and optimal support for each patient's complex, unique anatomy.

Fybrix

  • 2023
  • Enabling Technology
  • Venture Challenge
With Fybrix, we offer a synthetic, customizable and animal-free 3D cell culture material that uniquely mimics the native cell environment, in contrast to other synthetic materials that have been introduced in the market.

Gen-X

  • 2016
  • Enabling Technology
  • Venture Challenge
Next-generation gene promoters for more stable and higher recombinant protein expression.

GenomeTOX

  • 2022
  • Enabling Technology
  • Venture Challenge
Pionering whole genome sequencing based genotoxicity testing

Goal-3

  • 2019
  • Diagnostics
  • Venture Challenge
A robust patient monitoring device which is highly reliable and easy to use to prevent children in low and middle income countries unnecessary dying from severe bacterial infections.